Novartis AG has highlighted concerns about the delay in cancer diagnoses due to the COVID-19 pandemic and the impact it has had on the Swiss major's oncology business in the first quarter of 2021.
Speaking as Novartis posted total turnover of $12.41bn, down 2% at constant currencies, which included $3.78bn (+1%) from its oncology...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

